The Latent Tuberculosis Infection Detection Market Size is valued at USD 1.53 billion in 2023 and is predicted to reach USD 2.37 billion by the year 2031 at a 5.7% CAGR during the forecast period for 2024-2031.
Latent tuberculosis infection (LTBI) detection is a critical component of tuberculosis (TB) control, aiming to prevent the progression to active TB disease. Regular screening and effective detection strategies are vital for reducing TB incidence and controlling outbreaks. The latent tuberculosis infection detection market is experiencing growth due to the rising prevalence of tuberculosis worldwide. Various diagnostic methods, such as tuberculin skin tests, interferon-gamma release assays, and molecular tests, are used to detect latent tuberculosis infection. Factors driving market growth include increased awareness, government initiatives for tuberculosis control, and advancements in diagnostic technologies. Key market players are funding for research and development to introduce innovative detection methods.
The market is expected to continue expanding as healthcare systems focus on early detection and treatment of latent tuberculosis to prevent its progression to active disease. The rising risk of developing active disease from latent tuberculosis infection is one of the major driving factors for market growth. In addition, rising awareness about TB detection and various government initiatives for effective diagnosis and screening of tuberculosis infection are other factors contributing to market expansion.
The latent tuberculosis infection detection market segmentation includes segments based on Brand, Test Type, Application, and End-Use. As per the brand segment, the market consists of QFT-Plus (QuantiFERON-TB Gold Plus and Others. Based on Test Type, the market segments include Tuberculin Skin Test (TST) and Interferon Gamma Release Assay (IGRA). Based on Application, the market segments are Household Contacts with Pulmonary TB, PLHIV, and Others. Based on End-users, the market is segmented as Diagnostic Laboratories, Hospitals/Clinics, and Academic & Research Institutions.
The Hospitals/Clinics segment plays a vital role in the latent tuberculosis infection (LTBI) detection market. These healthcare settings are primary locations for diagnosing and managing LTBI due to their access to advanced diagnostic tools and specialized healthcare professionals. Hospitals and clinics conduct screening using methods like the Tuberculin Skin Test (TST) and Interferon-Gamma Release Assays (IGRAs). The growth of this segment is due to the rising prevalence of TB, increasing government and non-government initiatives for TB control, and the emphasis on early detection and treatment. Additionally, hospitals and clinics serve as key centres for implementing TB screening programs, especially in high-risk populations.
The tuberculin skin test (TST) segment is a crucial part of the detection market for latent tuberculosis infection (LTBI). It is widely used due to its simplicity, low cost, and established use in clinical practice. Despite its limitations, such as cross-reactivity with BCG vaccination and non-tuberculous mycobacteria, TST remains a standard screening tool, especially in resource-limited settings. The segment is driven by the ongoing need for TB control, government screening programs, and efforts to identify and treat LTBI in high-risk populations.
The North American latent tuberculosis infection detection market is projected to obtain the maximum market share. The opportunities in the form of unmet medical needs, scientific research, and economic growth are some primary growth drivers of this market. The rise of the healthcare regulatory scenario in countries is estimated to attract international players to capitalize and invest in existing opportunities. Asia Pacific is to be seen to grow at a rapid rate in the global latent tuberculosis infection detection market industries due to growing concerns about government initiatives and increasing funding in various ways.
| Report Attribute | Specifications |
| Market Size Value In 2023 | USD 1.53 Bn |
| Revenue Forecast In 2031 | USD 2.37 Bn |
| Growth Rate CAGR | CAGR of 5.7% from 2024 to 2031 |
| Quantitative Units | Representation of revenue in US$ Bn and CAGR from 2024 to 2031 |
| Historic Year | 2019 to 2023 |
| Forecast Year | 2024-2031 |
| Report Coverage | The forecast of revenue, the position of the company, the competitive market structure, growth prospects, and trends |
| Segments Covered | By Brand, Test Type, Application, End-Use |
| Regional Scope | North America; Europe; Asia Pacific; Latin America; Middle East & Africa |
| Country Scope | U.S.; Canada; U.K.; Germany; China; India; Japan; Brazil; Mexico; France; Italy; Spain; Southeast Asia; South Korea |
| Competitive Landscape | Wantai BioPharm, Lionex GmbH, QIAGEN, BIOMÉRIEUX, Oxford Immunotec, SD Biosensor INC., Sanofi, Serum Institute of India Pvt. Ltd, ARKRAY, Inc., Par Pharmaceutical, Inc., and others |
| Customization Scope | Free customization report with the procurement of the report and modifications to the regional and segment scope. Particular Geographic competitive landscape. |
| Pricing And Available Payment Methods | Explore pricing alternatives that are customized to your particular study requirements. |
Latent Tuberculosis Infection Detection Market By Test Type –
Latent Tuberculosis Infection Detection Market By Application –
Latent Tuberculosis Infection Detection Market By End-user –
Latent Tuberculosis Infection Detection Market By Region-
North America-
Europe-
Asia-Pacific-
Latin America-
Middle East & Africa-
Chapter 1. Methodology and Scope
1.1. Research Methodology
1.2. Research Scope & Assumptions
Chapter 2. Executive Summary
Chapter 3. Global Latent Tuberculosis Infection Detection Market Snapshot
Chapter 4. Global Latent Tuberculosis Infection Detection Market Variables, Trends & Scope
4.1. Market Segmentation & Scope
4.2. Drivers
4.3. Challenges
4.4. Trends
4.5. Investment and Funding Analysis
4.6. Industry Analysis – Porter’s Five Forces Analysis
4.7. Competitive Landscape & Market Share Analysis
4.8. Impact of Covid-19 Analysis
Chapter 5. Market Segmentation 1: by Brand Estimates & Trend Analysis
5.1. by Brand & Market Share, 2023 & 2031
5.2. Market Size (Value (US$ Mn)) & Forecasts and Trend Analyses, 2019 to 2031 for the following by Brand:
5.2.1. QFT-Plus (QuantiFERON-TB Gold Plus)
5.2.2. Others
Chapter 6. Market Segmentation 2: by Test Type Estimates & Trend Analysis
6.1. by Test Type & Market Share, 2023 & 2031
6.2. Market Size (Value (US$ Mn)) & Forecasts and Trend Analyses, 2019 to 2031 for the following by Test Type:
6.2.1. Tuberculin Skin Test (TST)
6.2.2. Interferon Gamma Released Assay (IGRA)
Chapter 7. Market Segmentation 3: by Application Estimates & Trend Analysis
7.1. by Application & Market Share, 2023 & 2031
7.2. Market Size (Value (US$ Mn)) & Forecasts and Trend Analyses, 2019 to 2031 for the following by Application:
7.2.1. Household Contacts with Pulmonary TB
7.2.2. PLHIV
7.2.3. Other
Chapter 8. Market Segmentation 4: by End User Estimates & Trend Analysis
8.1. By End User & Market Share, 2023 & 2031
8.2. Market Size (Value (US$ Mn)) & Forecasts and Trend Analyses, 2019 to 2031 for the following By End User:
8.2.1. Diagnostic Laboratories
8.2.2. Hospitals/Clinics
8.2.3. Academic & Research Institutions
Chapter 9. Latent Tuberculosis Infection Detection Market Segmentation 5: Regional Estimates & Trend Analysis
9.1. North America
9.1.1. North America Latent Tuberculosis Infection Detection Market Revenue (US$ Million) Estimates and Forecasts by Brand, 2024-2031
9.1.2. North America Latent Tuberculosis Infection Detection Market Revenue (US$ Million) Estimates and Forecasts by Test Type, 2024-2031
9.1.3. North America Latent Tuberculosis Infection Detection Market Revenue (US$ Million) Estimates and Forecasts by Application, 2024-2031
9.1.4. North America Latent Tuberculosis Infection Detection Market Revenue (US$ Million) Estimates and Forecasts by End User, 2024-2031
9.1.5. North America Latent Tuberculosis Infection Detection Market Revenue (US$ Million) Estimates and Forecasts by country, 2024-2031
9.2. Europe
9.2.1. Europe Latent Tuberculosis Infection Detection Market Revenue (US$ Million) Estimates and Forecasts by Brand, 2024-2031
9.2.2. Europe Latent Tuberculosis Infection Detection Market Revenue (US$ Million) Estimates and Forecasts by Test Type, 2024-2031
9.2.3. Europe Latent Tuberculosis Infection Detection Market Revenue (US$ Million) Estimates and Forecasts by Application, 2024-2031
9.2.4. Europe Latent Tuberculosis Infection Detection Market Revenue (US$ Million) Estimates and Forecasts by End User, 2024-2031
9.2.5. Europe Latent Tuberculosis Infection Detection Market Revenue (US$ Million) Estimates and Forecasts by country, 2024-2031
9.3. Asia Pacific
9.3.1. Asia Pacific Latent Tuberculosis Infection Detection Market Revenue (US$ Million) Estimates and Forecasts by Brand, 2024-2031
9.3.2. Asia Pacific Latent Tuberculosis Infection Detection Market Revenue (US$ Million) Estimates and Forecasts by Test Type, 2024-2031
9.3.3. Asia-Pacific Thermal Cyclers Asia-Pacific Latent Tuberculosis Infection Detection Market Revenue (US$ Million) Estimates and Forecasts by Application, 2024-2031
9.3.4. Asia-Pacific Latent Tuberculosis Infection Detection Market Revenue (US$ Million) Estimates and Forecasts by End User, 2024-2031
9.3.5. Asia Pacific Latent Tuberculosis Infection Detection Market Revenue (US$ Million) Estimates and Forecasts by country, 2024-2031
9.4. Latin America
9.4.1. Latin America Latent Tuberculosis Infection Detection Market Revenue (US$ Million) Estimates and Forecasts by Brand, 2024-2031
9.4.2. Latin America Latent Tuberculosis Infection Detection Market Revenue (US$ Million) Estimates and Forecasts by Test Type, 2024-2031
9.4.3. Latin America Latent Tuberculosis Infection Detection Market Revenue (US$ Million) Estimates and Forecasts by Application, 2024-2031
9.4.4. Latin America Latent Tuberculosis Infection Detection Market Revenue (US$ Million) Estimates and Forecasts by End User, 2024-2031
9.4.5. Latin America Latent Tuberculosis Infection Detection Market Revenue (US$ Million) Estimates and Forecasts by country, 2024-2031
9.5. Middle East & Africa
9.5.1. Middle East & Africa Latent Tuberculosis Infection Detection Market Revenue (US$ Million) Estimates and Forecasts by Brand, 2024-2031
9.5.2. Middle East & Africa Latent Tuberculosis Infection Detection Market Revenue (US$ Million) Estimates and Forecasts by Test Type, 2024-2031
9.5.3. Middle East & Africa Latent Tuberculosis Infection Detection Market Revenue (US$ Million) Estimates and Forecasts by Application, 2024-2031
9.5.4. Middle East & Africa Latent Tuberculosis Infection Detection Market Revenue (US$ Million) Estimates and Forecasts by End User, 2024-2031
9.5.5. Middle East & Africa Latent Tuberculosis Infection Detection Market Revenue (US$ Million) Estimates and Forecasts by country, 2024-2031
Chapter 10. Competitive Landscape
10.1. Major Mergers and Acquisitions/Strategic Alliances
10.2. Company Profiles
10.2.1. QIAGEN
10.2.2. BIOMÉRIEUX
10.2.3. Oxford Immunotec
10.2.4. SD Biosensor, INC.
10.2.5. Wantai BioPharm
10.2.6. Lionex GmbH
10.2.7. Sanofi
10.2.8. Serum Institute of India Pvt. Ltd
10.2.9. ARKRAY, Inc.
10.2.10. Par Pharmaceutical, Inc.
10.2.11. Abbott,
10.2.12. F. Hoffmann-La Roche Ltd,
10.2.13. Other Prominent Players